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Subcutaneous panniculitis-like T-cell lymphomas (SPTLs) represent a rare, difficult-to-diagnose, and poorly
characterized subtype of cutaneous T-cell lymphomas (CTCLs) affecting younger people more than the other
CTCL forms. We performed a thorough clinical, immunohistological, and molecular analysis of nine Finnish
SPTL patients. Specifically, we performed single-cell comparative genomic hybridization (CGH) from laser
microdissected, morphologically malignant SPTL cells, as well as loss of heterozygosity (LOH) and fluorescence
in situ hybridization (FISH) analysis for the NAV3 (neuron navigator 3) gene. CGH revealed large numbers of
DNA copy number changes, the most common of which were losses of chromosomes 1pter, 2pter, 10qter,
11qter, 12qter, 16, 19, 20, and 22 and gains of chromosomes 2q and 4q. Some of the DNA copy number
aberrations in SPTL, such as loss of 10q, 17p, and chromosome 19, overlap with those characteristic of common
forms of CTCL (mycosis fungoides (MF) and Sezary syndrome (SS)), whereas 5q and 13q gains characterize SPTL.
Allelic NAV3 aberrations (LOH or deletion by FISH), previously found in MF and SS, were identified in 44% of
the SPTL samples. This study demonstrates that SPTL is also moleculocytogenetically a uniform entity of CTCL
and supports the current World Health Organization–European Organization for Research and Treatment of
Cancer (WHO–EORTC) classification defining SPTL as a subgroup of its own.
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INTRODUCTION
Subcutaneous panniculitis-like T-cell lymphomas (SPTLs) are
a rare and poorly characterized subgroup of cutaneous T-cell
lymphomas (CTCLs). World Health Organization (WHO)
classification identifies SPTL as a separate entity of T-cell
lymphoma with an aggressive clinical behavior (Jaffe et al.,
2001), and the latest WHO–European Organization for
Research and Treatment of Cancer (WHO–EORTC) classifica-
tion separated for the first time two different subgroups within
SPTL (Willemze et al., 2005). Of these, only SPTL with a/b
T-cell phenotype (SPTL-AB), presenting with cells usually
expressing CD8, and restricted to the subcutaneous tissue
should be considered as SPTL. In the g/d T-cell phenotype
SPTL (SPTL-GD), the infiltrating malignant cells usually are
CD8 and CD56þ . They may show (epi)dermal involve-
ment and should be classified among the cutaneous g/d T-cell
lymphomas (Willemze et al., 2005; Willemze et al., 2008).
To date, there are only a few publications on SPTL,
describing mainly the clinicopathological characteristics of
sporadic cases (Burg et al., 1991; Salhany et al., 1998;
Weenig et al., 2001; Santucci et al., 2003; Hoque et al.,
2003; Massone et al., 2004, 2006; Takeshita et al., 2004,
Ghobrial et al., 2005). A very recent, as yet unpublished,
large clinicopathologic study of European patients has been
completed (Willemze et al., 2008). However, nothing is
known about the molecular mechanisms leading to SPTL.
Thus, we undertook a thorough clinical, immunohistological,
and molecular analysis of Finnish SPTL-AB patients and
present the results herein. Further usage of SPTL in this paper
presents SPTL-AB.
Clinically, SPTL presents with solitary or multiple sub-
cutaneous nodules and plaques, predominantly affecting
the lower extremities and trunk. Initial systemic symptoms
such as fever, fatigue, and weight loss are frequent, and
hemophagocytic syndrome may be present (Gonzalez et al.,
1991), indicating a rapidly progressive course and worse
prognosis (Marzano et al., 2000; Willemze et al., 2008).
Histologically, SPTL is characterized by subcutaneous infil-
trates of pleomorphic, small- to medium-sized T lymphocytes
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rimming the individual fat cells, whereas the epidermis and
dermis are typically uninvolved. Additionally, necrosis,
karyorrhexis, leukocytoclasia, and cytophagocytosis are often
present. The immunophenotype is usually CD3þ , CD4,
CD8þ , CD56, and cytotoxic proteins are frequently
expressed. The disease response to therapy is usually
favorable, with a 5-year survival of more than 80% (Massone
et al., 2004; Willemze et al., 2008) and without hemopha-
gocytic syndrome it is even 91% (Willemze et al., 2008).
RESULTS
Clinical and immunohistological features of SPTL
The patients were relatively young (13–59 years of age, mean
age 26 years; Table 1) when presenting with the first
symptoms compared with patients presenting with the more
common variants of CTCL, and there was a male predomi-
nance. The presenting symptoms were typically fever of
38–39 1C lasting for a few weeks and followed by the gradual
development of violaceous, subcutaneous plaques or nodules
anywhere on the body (Figure 1a). Before the diagnosis of
SPTL, most patients had undergone wide examinations to
reveal the cause of the fever, and the only abnormal
laboratory values common for these patients were as follows:
slight leukopenia, moderately elevated erythrocyte sedimen-
tation rate and C-reactive protein, and elevated lactate
dehydrogenase (Table 1). In whole-body computed tomo-
graphy and bone marrow biopsy, extracutaneous lymphoma
could not be verified, although it was suspected in two cases
(cases 2 and 3). The delay from the appearance of the first
symptoms to the definite SPTL diagnosis varied from 3 weeks
to 10 years. For three cases (cases 1, 2, and 4), the delay was
10 years, which further underlines the diagnostic challenges.
Cases 7–9 were diagnosed recently, and an accurate
diagnosis was achieved within a few months, due to
experience gained from this study. Three patients had a
history of autoimmune disease, one of idiopathic thrombo-
cytopenic purpura (ITP) (case 1), one of systemic lupus
erythematosus (SLE) (case 6), and one of psoriatic arthritis
(case 7). Additionally, SLE was suspected in three other cases
(cases 1, 2, and 7) because the skin lesions resembled lupus
skin lesions, but the American College of Rheumatology
(ACR) criteria for SLE (Tan et al., 1982) were not fulfilled.
Case 7 had been treated with antirheumatic drug leflunomide
for psoriatic arthritis before the onset of SPTL. None of the
patients fulfilled the hemophagocytic syndrome criteria,
although hemophagocytic syndrome was suspected in two
cases (cases 3 and 6).
Histologically, all skin biopsies exhibited an infiltrate of
small- to medium-sized pleomorphic cells with mitoses in the
deeper dermis and fat tissue. Lobular panniculitis and
rimming (atypical lymphocytes surrounding the fat cells in a
lace-like manner; Figure 1b) were present for all nine cases.
Additionally, erythrophagocytosis, karyorrhexis, and angio-
centricity were seen in the lymphoid infiltrate. The immuno-
phenotypes of the malignant cell infiltrate were CD3þ ,
CD4, CD8þ (Figure 1c), CD56, and GranzBþ in all nine
cases, whereas T cell-restricted intracellular antigen (TIA1)
was expressed in six cases. Active cell proliferation was
observed in all nine samples as measured by the nuclear
Ki-67 antigen expression (MIB-1 immunostaining). All cases
were positive for TCR a/b A chain (Figure 1d). No difference
in the clinical course was found in relation to these markers.
Common DNA copy number changes characteristic to SPTL,
as defined with CGH
To ensure the best possible representativeness of the sample
material, we chose to collect the morphologically malignant
cells by single-cell laser microdissection. The pure malignant
cell population thus obtained showed several previously
unreported DNA copy number abnormalities by comparative
genomic hybridization (CGH) (Figure 2). The overall CGH
profiles were consistent between individual patient samples,
and all samples showed chromosomal imbalances by CGH.
The number of chromosomal imbalances in case 3 was less
than in all other cases. The most common CGH findings were
DNA copy number losses in chromosomes 1p (6/6 cases), 2p
(5/6), 2q (4/6), 5p (5/6), 7p (4/6), 9q (5/6), 10q (5/6), 11q (5/6),
12q (5/6), 16 (5/6), 17q (4/6), 19 (4/6), 20 (6/6), 22 (6/6), and
gains in chromosomes 2q (5/6), 4q (5/6), 5q (4/6), 6q (4/6),
and 13q (4/6) (Figure 2).
NAV3 deletion is found in SPTL by fluorescence in situ
hybridization and loss of heterozygosity analysis
Deletion of NAV3 (neuron navigator 3) gene, previously found
to be associated with mycosis fungoides (MF) and Sezary
syndrome (SS) (Karenko et al., 2005), by fluorescence in situ
hybridization (FISH) on touch preparates made from fresh
frozen tissue skin biopsy samples, was demonstrable in 34, 52,
and 8% of the cells of the three patient samples studied (cases
2, 3, and 8, respectively). Loss of heterozygosity (LOH) results
for the NAV3 region in the skin samples could be obtained
from four patients. Three patients (cases 2, 3, and 5) showed
LOH at D12S326, the closest marker relative to NAV3, and in
two of these (cases 2 and 3), marker D12S1684 was shown to
be involved as well. Case 6 was uninformative for D12S326
but showed LOH at D12S1684.
DISCUSSION
This study reveals DNA copy number changes common to
SPTL. Previously, it has proven to be difficult to obtain any
molecular cytogenetic data on SPTL, because the number of
malignant cells circulating in the blood, if any, is scarce, and
the malignant cells in the subcutaneous tissue are surrounded
by fat cells, reactive T cells, and other normal cells of the
skin. By microdissecting the morphologically malignant cells
from the biopsy sections of SPTL lesions, isolating the
genomic DNA thereof, and amplifying the obtained DNA
with a reliable whole-genome amplification method, it was
possible to assess the DNA copy number changes occurring
in the malignant cell population of SPTL.
CGH revealed DNA copy number aberrations in the
majority of the chromosomes. The large amount of aberra-
tions is due to the relatively pure malignant cell population
that was studied. The DNA copy number changes were very
uniform between individual patients with a large number
of changes occurring in the vast majority of cases (Figure 2).
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Table 1. Clinical presentation, treatment and outcome of the patients
Case
Sex and age
(years) at
time of first
symptoms
First clinical presentation
and abnormal laboratory
parameters Initial therapy Staging (CT or BM)
Therapy after
SPTL diagnosis Outcome
1 F, 18 Recurrent fever and subcutaneous
nodules in extremities and face,
loss of weight; SR 27, CRP 14,
WBC 3.2109 l1, LD 1,206U l1
Prednisone-
remission for 5 years;
azathioprine,
hydroxychloroquine
CT: negative Cytostatics (M-BAIOD/
BACOD 6 cycles)
CR for 7 years
2 M, 16 Recurrent fever, 2 years later
subcutaneous nodules on trunk and
later on extremities; SR 19, CRP 31,
WBC 1.9109 l1, LD 1,125U l1
Hydroxychloroquine CT: negative
BM: negative
Cytostatics
(CHOP 6 cycles)
CR for 4 years
3 M, 13 Fever for 4 weeks and
subcutaneous nodules on face,
trunk, and extremities, fatigue,
dry cough; SR 16, CRP 35, WBC
3.1109 l1, ALAT 123, ASAT
125, prealbumin 43mg l1, LD
1,581U l1
Antimicrobials CT: liver involvement
suspected, pleural
effusion and slight
ascites (HPS criteria
not fulfilled)
BM: negative
Prednisone+
cyclophosphamide,
CHOP-E1, 3 cycles-
PR in skin, sepsis;
relapse 1 month
later, melphalan+
autologous stem
cells twice2
Died of
Pseudomonas
sepsis, complicating
autologous stem
cell transplants,
6 months after
first symptoms
of SPTL
4 M, 18 Fever and subcutaneous plaques,
patches and nodules on trunk
and extremities, during relapse
weight loss; LD 2,084U l1,
WBC 2.5109 l1
Prednisone-
remission for
10 years
CT: negative
BM: negative
Cytostatics
(M-BACOD
6 cycles)
CR for 6 years
5 M, 23 Recurrent fever and tender
subcutaneous violaceous nodules
on face, trunk, arms, and legs,
weight loss; WBC 2.8 109 l1,
SR 35, ASAT 338, ALAT 417,
AFOS 1,180, LD 4,320U l1
Prednisone-no
remission
CT: ND
BM: infiltration of
histiocytes with
erythrophagocytosis
in spleen-
splenectomy
Cytostatics
(Bleo-CHOP
3 cycles)
CR for 18 years
6 F, 48 Recurrent fever episodes,
subcutaneous nodules; WBC
1.7109 l1, platelets
105109 l1, S-ferritin
4,800 mg l1, ASAT 254, ALAT 122,
AFOS 830, LD 1,063U l1; SLE
diagnosis 19 years earlier with
complications (hepatitis, AIHA,
thrombocytopenia)
Prednisone-no
remission
Cyclosporine,
azathioprine,
methylprednisolone
Symptoms were
considered SLE
related
CT: negative
BM: negative
Cytostatics (CHOP
7 cycles);
radiotherapy
for local
recurrence
CR for 5 years
7 F, 59 Subcutaneous violaceous
nodules on forehead and
arms; no B-symptoms;
LD 239U l1
CT: negative
BM: ND
Electron beam-
partial response
Prednisone 60mg for
2 weeks, reduction
to 10mg within
3 months-CR
CR; follow-up
time o2 years
8 M, 27 Subcutaneous, firm nodules
on top of the head; no
B-symptoms
CT: negative
BM: negative
Prednisone 60mg-
CR, relapse within
1 month-
prednisone 80mg for
2 weeks, reduction
to 5mg within
5 months-CR
CR; follow-up
time o2 years
9 F, 15 Subcutaneous, tender nodules
on upper and lower extremities
and abdomen; no B-symptoms;
LD 242U l1
CT: ND
BM: ND
Prednisone 40mg
for 2 weeks, end of
the treatment within
6 weeks-CR
CR; follow-up time
o2 years
AFOS, alkaline phosphatase; AIHA, autoimmune hemolytic anemia; ALAT, alanine amino transferase; ASAT, aspartate aminotransferase; BM, bone marrow;
CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CR, complete remission; CRP, C-reactive protein; CT, computed tomography; F, female;
HPS, hemophagocytic syndrome; LD, lactate dehydrogenase; M, male; M-BACOD, methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine,
dexamethasone; M-BAIOD, methotrexate, bleomycin, doxorubicin, ifosfamide, vincristine, dexamethasone; ND, not determined; PR, partial response; SR,
sedimentation rate; WBC, white blood cell.
1CHOP-E=cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide, combined with G-CSF as described in the Nordic Lymphoma Group phase II
study of peripheral T-cell lymphomas (NLG-T-01) (Sendoxan, Adriamycin, VP16, Oncovin).
2Autologous stem cells second time after busulfan, thiotepa, etoposide, and ARA-C.
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In previous CGH studies on other CTCL forms, performed on
non-microdissected heterogeneous cell populations, the
CGH changes identified have not been that uniform,
although they were common to the majority of cases studied
(Karenko et al., 1999; Mao et al., 2002; Fischer et al., 2004).
In this SPTL patient series, the number of losses in DNA
copy number exceeded the number of gains. This has also
been the trend in some previous CGH studies of the most
common CTCL subgroups, for example, MF and SS (Karenko
et al., 1999). DNA copy number gains were detected in large
areas in the q-arms of chromosomes 2, 4, 5, and 13 (Figure 2).
Previous CGH studies on MF and SS have demonstrated gains
in chromosomes 2q (Mao et al., 2002; Karenko et al., 1999)
and 4q (Mao et al., 2002; Hahtola et al., 2006). By gene
expression analysis of these common CTCL subtypes,
chromosome arm 4q is also among the areas with the highest
frequency of upregulated genes (Hahtola et al., 2006). Losses
were identified in the terminal parts of many chromosomes,
as well as covering the whole small group F and G
chromosomes. The most common areas of DNA copy
number losses were 1qter, 2qter, 10qter, 11qter, 12qter,
17p, 19, 20, and 22. These findings also share a great deal of
similarities when compared to the CGH findings published
for the most common CTCL subgroups. Chromosomal losses
of 1p, 17p, 10q, and 19 were the most common CGH
changes in a British study of 34 CTCL patients (Mao et al.,
2002), and other groups have demonstrated losses of 10q and
17p to be the key aberrations in CTCL (Karenko et al., 1999;
Fischer et al., 2004). On the other hand, losses of chromo-
somes 5q and 13q occur in the most common forms of CTCL
(Karenko et al., 1999; Fischer et al., 2004), but in SPTL these
areas showed DNA copy number gains by CGH. Our current
finding of losses in chromosome 12q, in most cases of SPTL,
is in concordance with the recent identification of both DNA
copy number loss and a downward gene expression bias in
chromosome 12q (Hahtola et al., 2006). We also recently
reported on the recurrent CTCL-associated gene aberration,
a putative, previously unknown, non-classical (that is,
Figure 1. Clinical and immunohistological characteristics of SPTL. (a) SPTL
presents clinically with subcutaneous, usually multiple reddish nodules on the
trunk and extremities. (b) Histologically, SPTL is characterized by atypical
lymphocytes rimming the subcutaneous adipocytes. Immunohistologically,
SPTL is characterized by (c) CD8 positive and (d) TCR a/b infiltrating
lymphocytes.
1 2 3 4 5
6 7 8 9 10 11 12
13
19 20 21 22 X Y
14 15 16 17 18
Figure 2. DNA copy number changes of true malignant cells of seven patients with SPTL. The most common CGH findings were DNA copy number losses in
chromosomes 1p (6/6 cases), 2p (5/6), 5p (5/6), 9q (5/6), 10q (5/6), 11q (5/6), 12q (5/6), 16 (5/6), 20 (6/6), 22 (6/6), and gains in chromosomes 2q (5/6) and 4q (5/6).
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haploinsufficient) tumor suppressor gene NAV3, located in
the chromosomal area 12q21, to be deleted or translocated
in all stages of CTCL (Karenko et al., 2005). NAV3 was
also deleted in the four SPTL patients studied, as detected by
both FISH and LOH analyses, and thus the NAV3 gene seems
to be important for several CTCL subtypes, namely MF, SS,
and SPTL. Taken together, in addition to NAV3 deletion,
chromosome regions 10q, 17p, and 19 are likely to harbor
genes common for the molecular pathogenesis of several
subtypes of CTCL (MF, SS, and SPTL), whereas 5q and 13q
gains characterize SPTL.
It may be speculated that aberrations in chromosome
arms, common to both SPTL and MF/SS, may not influence
the prognosis, as the prognosis of SPTL is favorable and that
of SS less favorable. It has previously been observed that
17p loss and 7 gain do not influence the prognosis of CTCL
(MF and SS) patients (Fischer et al., 2004). Instead, 13q loss
has previously been found to associate with shorter survival
among MF and SS patients (Fischer et al., 2004) and,
interestingly, SPTL patients did not show that abnormality,
but instead, frequently have 13q gain.
Our findings also provide previously unknown information
on the usage of systemic steroids as a first-line therapy for SPTL.
Although it took almost 10 years to reach the definite SPTL
diagnosis for three of our first cases, they were all treated with
oral steroids for unclassified panniculitis, and long-lasting
remissions, even for 10 years, were achieved. Moreover, three
of the more recent patients (cases 7–9) have responded
completely to long-term systemic steroid therapy. However,
the factors determining response to sole high-dose systemic
corticosteroid therapy and the requirement of multiagent
chemotherapy need to be defined in a larger prospective study.
Autoimmune phenomena occur frequently among SPTL
patients (Willemze et al., 2008). Three of our cases had an
autoimmune disease, and two other cases presented with
laboratory abnormalities suggestive of an autoimmune
disorder, for example, antinuclear autoantibodies, a positive
Coombs test, but the criteria for any specific autoimmune
disease were not fulfilled. It is noteworthy that the
autoimmune phenomena (either a confirmed autoimmune
disease or sole laboratory abnormalities) of four of our cases
(cases 1, 2, 4, and 6) completely disappeared after the
successful treatment of SPTL with multiagent chemotherapy.
This observation supports a link between the autoimmune
disorder and the development of SPTL. However, such
association still needs to be confirmed in a multinational
prospective study.
Taken together, our findings demonstrate the clinical and
immunohistological characteristics of SPTL with the a/b
T-cell phenotype. In addition, CGH revealed previously
unidentified DNA copy number abnormalities, some of
which were common with other CTCL subtypes, but a great
number were also SPTL specific, namely gains of 5q and 13q.
Thus, the WHO–EORTC classification of SPTL as being a
separate CTCL subgroup is also confirmed at a molecular
cytogenetic level. Moreover, demonstration of a NAV3 gene
deletion by FISH was found to characterize SPTL apart from
the more common CTCL subtypes MF and SS.
MATERIALS AND METHODS
Patient samples
Nine patients diagnosed with SPTL were included in the study
(Table 1). All patients were treated at the Helsinki University Central
Hospital between 1987 and 2007, and the study was approved by
the ethical review boards of Helsinki and Uusimaa Hospital District
and of the Skin and Allergy Hospital, Helsinki University Central
Hospital. The additional skin and blood samples obtained for this
study were obtained with the patient’s (or parents’ in the case of
children) informed consent.
Sections cut from the paraffin-embedded biopsies were immuno-
stained for membrane antigens (manufacturer and dilutions are given
in parentheses) CD3 (Novocastra, New Castle, UK; 1:100), CD4
(Novocastra; 1:150), CD5 (Novocastra; 1:25), CD7 (Novocastra;
1:100), CD8 (Novocastra; 1:25), CD30 (Dako, Glostrup, Denmark;
1:25), CD56 (Zymed, South San Francisco, CA; 1:50), Granzyme B
(Monosan, Uden, The Netherlands; 1:100), TIA1 (Biocare, Birmingham,
UK; 1:200), Ki-67 (MIB-I antibody, recognizes proliferating cells at
all stages of the cell cycle but not cells in G0 phase, Dako; 1:50), and
TCR a/b (GeneTex, TX; 1:100) according to the manufacturers’
instructions and visualized with DakoEnvision (Dako).
DNA extraction
Sections of 5mm were cut from formalin-fixed paraffin-embedded
tissue samples (n¼ 6) using a microtome and mounted onto a 1.35-
mm-thin polyethylene membrane (PALM Microlaser Technologies,
Bernried, Germany) attached to a glass slide. Tissue sections were
then deparaffinized and stained with hematoxylin (Stoecklein et al.,
2002) and hematoxylin–eosin for morphological control (standard
protocol). Single lymphocytes or areas of malignant lymphocytes
rimming the fat lobules covering altogether 50,000 mm2 were laser
capture microdissected using the PALM Laser-Microbeam System
(PALM Microlaser Technologies). Thereafter, proteinase K digestion
was performed and the DNA was amplified with single-cell CGH, as
previously described (Klein et al., 1999; Stoecklein et al., 2002). The
success of the amplification was PCR-tested with microsatellite
markers D5S500 and D17S1161, as previously described (Stoecklein
et al., 2002). Isolation of genomic DNA was successful in all seven
cases. The amplified DNA of the microdissected cells was then used
for CGH and LOH analyses, as described below.
Comparative genomic hybridization
CGH was performed as previously described (Klein et al., 1999;
Stoecklein et al., 2002). Briefly, microdissected and proteinase
K-digested DNA was digested with MseI restriction enzyme
(New England BioLabs, Ipswich, MA), adaptors were ligated to
the 50 overhangs, and DNA fragments were amplified by PCR.
The amplified DNA was then labeled with digoxigenin-dUTP
(Roche, Mannheim, Germany) and similarly processed aliquots of
reference DNA obtained from peripheral blood mononuclear cells
of healthy volunteers with biotin-dUTP (Roche). The labeled probes
were hybridized on normal male metaphase slides for 2–3 nights.
After post-hybridization washes, metaphases were viewed under
a fluorescence microscope and three-color digital images were
captured using an epifluorescence microscope (Axioplan imagining
2; Carl Zeiss AG, Oberkochen, Germany) equipped with a CCD
camera. Images were analyzed with ISIS digital image analysis system
(MetaSystems GmbH, Altlussheim, Germany) using statistical limits for
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green to red ratios to determine DNA copy number gains and losses.
For each case, 8–12 metaphases were included in the analysis. As an
internal control, normal male and female DNA was cohybridized and
only differences in sex chromosomes were identified.
Locus-specific FISH for NAV3
Interphase FISH was performed on frozen tissue samples of four
patients (cases 2, 3, 7, and 9, of whom enough material was
available) to identify deletion of NAV3 gene by using NAV3-specific
bacterial artificial chromosomes (BACs), as previously described
(Karenko et al., 2005). Briefly, digoxigenin-labeled BACs, 136F16
and 36P3, spanning the frequently deleted area of NAV3 gene were
cohybridized with biotin-labeled chromosome 12 centromere
on touch preparates made of frozen tissue samples. After post-
hybridization staining with anti-digoxigenin rhodamine and avidin-
FITC (both from Invitrogen, Carlsbad, CA), the interphase nuclei
were viewed under a fluorescence microscopy and signals were
counted from the BACs and centromeres in at least 50 non-
overlapping nuclei of each case. A nucleus with an equal number of
fluorescence signals from the centromere probe and the BAC probes
was considered normal, and a deletion was recorded if the
centromere probe gave a higher number of signals than the BAC
probes. A cutoff level for at least 10% of abnormal nuclei was
introduced based on our previous expertise on lymphoma and non-
lymphoma skin lesions (Karenko et al., 2005).
NAV3 LOH analysis
For NAV3 LOH analysis, we chose three microsatellite markers
spanning the NAV3 gene locus at 12q21.2–q21.31 and surrounding
the gene from both directions (physical distances between loci in
mega-bases according to http://www.ensembl.org are given in
parentheses): pter D12S1684-(0.8Mb)-D12S326-(0.2Mb)-NAV3-
(3.8Mb)-D12S1708 qter. The PCR amplification primers were
D12S1684F 50-cctgcatgcctcagttatga-30, D12S1684R 50-aacaagccata
ccagtcagg-30, D12S326F 50-accaggctcccctaaaagtg-30, D12S326R
50-agaatgaccagacccacagg-30, D12S1708F 50-gggaacttatgtcaaggctag
ga-30, D12S1708R 50-gatctagtgctcaagaggttttcaa-30. The forward
primers were fluorescently labeled with 6-carboxyfluorescein, the
PCR fragments were run on the ABI3730 sequencer/genotyper, and
the results analyzed using GeneMapper v3 software (Applied
Biosystems Europe/Applera Finland, Espoo, Finland). A sample was
scored as showing LOH if one of the alleles in the tumor sample had
decreased 40% or more compared to its matching normal.
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